{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:06:19Z","timestamp":1792087579118,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejca.2024.113564","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T20:50:10Z","timestamp":1705697410000},"page":"113564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives"],"prefix":"10.1016","volume":"199","author":[{"given":"Britte H.E.A","family":"ten Haaft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pedregal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-1823","authenticated-orcid":false,"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ejca.2024.113564_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/liv.14089","article-title":"Surgery for cholangiocarcinoma","volume":"39","author":"Cillo","year":"2019","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.ejca.2024.113564_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience With 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"14","key":"10.1016\/j.ejca.2024.113564_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2024.113564_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2024.113564_bib5","unstructured":"KEYNOTE-966 trial. Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04003636\u3009."},{"issue":"10391","key":"10.1016\/j.ejca.2024.113564_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2024.113564_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2024.113564_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells12162098","article-title":"Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.ejca.2024.113564_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206007","article-title":"The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers","volume":"13","author":"Lamarca","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastas- Rev"},{"issue":"9","key":"10.1016\/j.ejca.2024.113564_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ejca.2024.113564_bib12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.113564_bib13","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma With IDH1 Mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.113564_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.113564_bib15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.ejca.2024.113564_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1097-2765(03)00048-0","article-title":"The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors","volume":"11","author":"Garrett","year":"2003","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab-mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.113564_bib18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","article-title":"ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer","volume":"15","author":"Karunagaran","year":"1996","journal-title":"Embo J"},{"issue":"5","key":"10.1016\/j.ejca.2024.113564_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2024.113564_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tig.2006.06.007","article-title":"Gene amplification in cancer","volume":"22","author":"Albertson","year":"2006","journal-title":"Trends Genet"},{"issue":"3","key":"10.1016\/j.ejca.2024.113564_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1534\/genetics.111.136911","article-title":"Gene overexpression: uses, mechanisms, and interpretation","volume":"190","author":"Prelich","year":"2012","journal-title":"Genetics"},{"issue":"45","key":"10.1016\/j.ejca.2024.113564_bib22","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2024.113564_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pharmthera.2019.03.010","article-title":"Prevalence and role of HER2 mutations in cancer","volume":"199","author":"Cocco","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"9742","key":"10.1016\/j.ejca.2024.113564_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2024.113564_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"4717","key":"10.1016\/j.ejca.2024.113564_bib26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","article-title":"Amplification of a novel v-erbB-related gene in a human mammary carcinoma","volume":"229","author":"King","year":"1985","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ejca.2024.113564_bib27","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann Oncol"},{"issue":"1-2","key":"10.1016\/j.ejca.2024.113564_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000511919","article-title":"ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway","volume":"44","author":"Jacobi","year":"2021","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ejca.2024.113564_bib29","article-title":"HER2 Aberrations as a novel marker in advanced biliary tract cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.113564_bib30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00535-014-0984-5","article-title":"Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab","volume":"50","author":"Kawamoto","year":"2015","journal-title":"J Gastroenterol"},{"issue":"12","key":"10.1016\/j.ejca.2024.113564_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejca.2024.113564_bib32","series-title":"Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets","author":"Holcombe","year":"2015"},{"issue":"8","key":"10.1016\/j.ejca.2024.113564_bib33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/modpathol.2015.57","article-title":"Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2)","volume":"28","author":"Hechtman","year":"2015","journal-title":"Mod Pathol"},{"issue":"17","key":"10.1016\/j.ejca.2024.113564_bib34","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.01.005","article-title":"HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting","volume":"143","author":"Kol","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"31","key":"10.1016\/j.ejca.2024.113564_bib36","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.113564_bib37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.ejca.2024.113564_bib38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother Pharm"},{"issue":"3","key":"10.1016\/j.ejca.2024.113564_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336488","article-title":"HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib","volume":"82","author":"Peck","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2024.113564_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S55091","article-title":"Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab","volume":"9","author":"Sorscher","year":"2013","journal-title":"Cancer Manag Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.113564_bib41","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.113564_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.113564_bib43","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or <em>HER2<\/em>-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib44","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"17_suppl","key":"10.1016\/j.ejca.2024.113564_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.113564_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4007","article-title":"Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): a phase 2 basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.113564_bib47","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19\u201314)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2024.113564_bib49","first-page":"Jco2301193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2-positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","author":"Ostwal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2468-1253(22)00352-1","article-title":"Practicalities accessing precision medicine in biliary tract cancer","volume":"8","author":"Edeline","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2024.113564_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.ejca.2024.113564_bib53","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","article-title":"HER2-Overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2","volume":"23","author":"Hanker","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.113564_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ejca.2024.113564_bib55","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12253-020-00844-w","article-title":"Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers","volume":"26","author":"Niu","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.113564_bib56","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/cas.13314","article-title":"Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer","volume":"108","author":"Gao","year":"2017","journal-title":"Cancer Sci"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.113564_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4097","article-title":"Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial","volume":"41","author":"Ohba","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113564_bib58","unstructured":"J. Priour, Z. HERIZON-BTC-02."},{"key":"10.1016\/j.ejca.2024.113564_bib59","unstructured":"Astra Zeneca. Enhertu demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumours. 2023; Available from: \u3008https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/enhertu-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing.html\u3009."},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib60","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv"},{"issue":"7_Supplement","key":"10.1016\/j.ejca.2024.113564_bib61","article-title":"Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2024.113564_bib62","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.2533","article-title":"A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors","volume":"40","author":"Reiss","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2024.113564_bib63","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2549","article-title":"Preliminary results from a phase 1\/2 study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors","volume":"39","author":"Sharma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib64","article-title":"Targeting toll-like receptor 7\/8 for immunotherapy: recent advances and prospectives","volume":"10","author":"Sun","year":"2022","journal-title":"Biomark Res"},{"issue":"8","key":"10.1016\/j.ejca.2024.113564_bib65","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.ejca.2024.113564_bib66","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","article-title":"Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations","volume":"34","author":"Pahuja","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ejca.2024.113564_bib67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.ejca.2024.113564_bib68","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2023.03.016","article-title":"Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)","volume":"18","author":"Cornelissen","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2024.113564_bib69","unstructured":"ASCO. Tuxobertinib (BDTX-189), an irreversible selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. 2020; Available from: \u3008https:\/\/ascopubs.org\/toc\/jco\/38\/15_suppl\u3009."},{"issue":"8","key":"10.1016\/j.ejca.2024.113564_bib70","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/DCR.0000000000002106","article-title":"Favorable survival after screening for young-onset colorectal cancer: benefits of screening in young adults","volume":"65","author":"Takada","year":"2022","journal-title":"Dis Colon Rectum"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:26Z","timestamp":1760733746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":70,"alternative-id":["S0959804924000406"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113564","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113564"}}